Aspira Women's Health
AWH

$0.9620

0.21%

Market Cap: $15.5M

About: Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its products include OvaSuite which is a portfolio of blood tests that applies proprietary algorithms incorporating patient features; OvaWatch intended for use in assessing the risk of ovarian cancer for women with adnexal masses; and Ova1Plus is a portfolio of blood tests, Ova1Plus is a combination of two FDA-cleared tests for women with pelvic masses who are planned for surgery.

Employees: 64

Healthcare In Vitro & In Vivo Diagnostic Substances

0

Funds holding %

of 6,710 funds

–

Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

80% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 5

13% more funds holding

Funds holding: 23 [Q1] → 26 (+3) [Q2]

9.1% more ownership

Funds ownership: 2.11% [Q1] → 11.21% (+9.1%) [Q2]

66% less capital invested

Capital invested by funds: $6.16M [Q1] → $2.08M (-$4.08M) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5.50

472%

upside

Avg. target

$5.50

472%

upside

High target

$5.50

472%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Alliance Global Partners

Ben Haynor

43% 1-year accuracy

3 / 7 met price target

472%upside

$5.50

Buy

Maintained

14 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about AWH published over the past 30 days

Aspira Women's Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference

AUSTIN, Texas, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that Nicole Sandford, CEO of Aspira Women's Health will present at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.

Aspira Women's Health to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Zacks Investment Research

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

AWH's partnership with Dorsata is set to help with the adnexal masses diagnosis and treatment.

Dorsata's Alliance on Adnexal Masses to Support Aspira Stock

Aspira Women's Health Inc. (AWH) Q2 2024 Earnings Call Transcript

Aspira Women's Health Inc. (NASDAQ:AWH ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Nicole Sandford - CEO and Director Sandy Milligan - President Conference Call Participants Ross Osborn - Cantor Fitzgerald Do Kim - Water Tower Research Operator Good morning, ladies and gentlemen. And welcome to Aspira Women's Health, Incorporated Second Quarter 2024 Earnings Conference Call.

Aspira Women's Health Inc. (AWH) Q2 2024 Earnings Call Transcript

Zacks Investment Research

Aspira (AWH) Reports Q2 Loss, Misses Revenue Estimates

Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago.

Aspira (AWH) Reports Q2 Loss, Misses Revenue Estimates

Aspira Women's Health Reports Second Quarter 2024 Financial Results

Q2 2024 OvaSuite S M revenue of $2.4 million and volume of 6,471 units

Aspira Women's Health Reports Second Quarter 2024 Financial Results

Aspira Women's Health's Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women's Health (NPWH) Women's Healthcare Conference

AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a poster presentation at the 27th Annual National Association of Nurse Practitioner's in Women's Health (NPWH) Woman's Healthcare Conference being held on September 25-28, 2024, in Chicago, IL. Presentation details are as follows:

Aspira Women's Health's Announces a Poster Presentation at the 27th Annual National Association of Nurse Practitioners in Women's Health (NPWH) Women's Healthcare Conference

Aspira Women's Health Announces Closing of $1.9 Million Private Placement Equity Financing

AUSTIN, Texas, July 09, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that it has closed its previously announced private placement for the issuance and sale of shares of the Company's common stock and accompanying warrants to purchase an equal number of shares for gross proceeds of approximately $1.9 million. Aspira has the potential to receive additional gross proceeds of up to $2.8 million, before deducting offering expenses, upon the full cash exercise of warrants issued in the private placement.

Aspira Women's Health Announces Closing of $1.9 Million Private Placement Equity Financing

Aspira Women's Health Announces $1.935 Million Private Placement Equity Financing

AUSTIN, Texas, July 01, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced it has entered into a securities purchase agreement dated June 30, 2024 with certain existing accredited shareholders and Company insiders to issue and sell an aggregate of 1,264,739 shares of its common stock (“Common Stock”) and warrants to purchase an equal number of shares of Common Stock (“Warrants”) at a combined offering price of $1.53 per share and warrant through a private placement financing (the “Offering”). Aspira anticipates the gross proceeds from the Offering will be approximately $1.935 million, before deducting offering expenses. The warrants will be exercisable for three years after date of issuance and have an exercise price of $2.25 per share. The Offering is expected to close by July 8, 2024 subject to customary closing conditions. Net proceeds from the Offering will support Aspira's ongoing commercial activities as well as general corporate purposes and working capital.

Aspira Women's Health Announces $1.935 Million Private Placement Equity Financing

Aspira Women's Health Provides Commercial, Reimbursement and Cash Guidance Updates

Monthly OvaSuiteSM product volume grew by more than 26% in May compared to January Reimbursement momentum continued with expanded Anthem and Medicaid coverage for OvaSuite Cash used in operations guidance for 2024 expected to be lowered AUSTIN, Texas, June 13, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today provided interim commercial and operational updates for the second quarter of 2024. Product volume continued its sustained monthly gains, growing by more than 26% in May 2024 compared to January 2024.

Aspira Women's Health Provides Commercial, Reimbursement and Cash Guidance Updates

Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21

AUSTIN, Texas, May 16, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced that management will present a corporate overview at the Alliance Global Partner's Healthcare Showcase taking place virtually on Tuesday, May 21, 2024.

Aspira Women's Health to Present at the A.G.P. Healthcare Showcase on May 21

See News Rankings